« Back
Home /
Biotinylated Human HLA-A*03:01&B2M&gp100 (ALLAVGATK) Monomer Protein (MHC-HM463B)

Biotinylated Human HLA-A*03:01&B2M&gp100 (ALLAVGATK) Monomer Protein (MHC-HM463B)

Item no.	MHC-HM463B-100UG
Manufacturer	KactusBio
Amount	100 ug
Quantity options	100 ug 500 ug
Category	Oncology By Cell Type Carcinoma Glioma Hematology Leukemia Lymphoma Myeloma Melanoma Peptides & Proteins Recombinant Proteins Adenocarcinoma Myelofibrosis Mesothelioma Astrocytoma By Organ Heart & Blood Cancer Blastom
Type	Proteins Recombinant
Format	Lyophilized
Specific against	Human (Homo sapiens)
Host	HEK293
Conjugate/Tag	HIS, Avi
Purity	> 95% as determined by Bis-Tris PAGE;> 95% as determined by HPLC
Sequence	Gly25-Thr305(HLA-A*03:01), Ile21-Met119(B2M) and ALLAVGATK peptide
NCBI	ALLAVGATK
ECLASS 10.1	32160409
ECLASS 11.0	32160409
UNSPSC	12352202
Alias	gp100 (ALLAVGATK)
Shipping Condition	Room temperature
Available
Manufacturer - Type	Recombinant Protein
Manufacturer - Targets	HLA-A*03:01&B2M&gp100 (ALLAVGATK)
Manufacturer - Conjugate / Tag	C-His-Avi
Shipping Temperature	Shipped at ambient temperature.
Storage Conditions	-20 to -80°C for 12 months as supplied from date of receipt.；-80°C for 3 months after reconstitution.；Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Molecular Weight	The protein has a predicted MW of 50.15 kDa. Due to glycosylation, the protein migrates to 51-60 kDa based on Bis-Tris PAGE result.
Description	Recombinant Biotinylated Human HLA-A03:01&B2M&gp100 (ALLAVGATK) Monomer Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus.It contains Gly25-Thr305 (HLA-A03:01), Ile21-Met119 (B2M) and ALLAVGATK peptide.
Background	Immunization against the ALLAVGATK peptide may occur in melanoma patients and that the immunogenicity of this peptide is similar to that of the majority of melanoma differentiation antigens defined to date. Therefore, the use of ALLAVGATK in active immunotherapy for HLA-A3 melanoma patients, for whom no other immunogenic peptide has been so far described, remains a distinct possibility, providing that patients treated in vivo with this peptide develop a better in vitro response than already demonstrated for HLA-A2 epitopes generated from this same antigenic protein.
Endotoxin	Less than 1 EU per μg by the LAL method.
Formulation	Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution	Dissolve the lyophilized protein in distilled water. It is recommended to resuspend at 0.5 mg/mL if the lyophilized powder is 100 μg or less, at 1mg/ml for 500μg or 1mg lyophilized powder. Do not mix by vortex or vigorous shaking.
Biotinylated	yes

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

MHC-HM463B-100UG-datasheet.pdf

MHC-HM463B-100UG-safety-datasheet.pdf